Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 10,628 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Healthy or Stable Chronic Illness
Interventions: Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 2,312 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 110
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 95 more

Conditions: Leukemia
Interventions: asparaginase, busulfan, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, methotrexate, mitoxantrone hydrochloride, allogeneic bone marrow transplantation; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 134
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 111 more

Conditions: Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 16
States / cities: Murrieta, California • Rialto, California • Ventura, California + 13 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Pravastatin; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hemmorhagic Shock During Air Medical Transport
Interventions: infusion of 2 units of plasma; Biological
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 90 Years
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Coronary Syndrome
Interventions: 99mTc-glucarate solution; Drug
Lead sponsor: Molecular Targeting Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • New Haven, Connecticut • Cleveland, Ohio + 1 more

Conditions: Advanced Solid Tumors
Interventions: Tarceva, erlotinib, OSI-774; Drug
Lead sponsor: OSI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Santa Monica, California • Aurora, Colorado • Rochester, Minnesota + 1 more

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: VT-1161, Placebo; Drug
Lead sponsor: Viamet; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more

Conditions: Pulmonary Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: sodium phenylbutyrate; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 10
States / cities: Iowa City, Iowa • Lexington, Kentucky • Baltimore, Maryland + 7 more

Conditions: Traumatic Brain Injury
Interventions: Glyburide, Placebo; Drug
Lead sponsor: Remedy Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: San Diego, California • Baltimore, Maryland • Pittsburgh, Pennsylvania + 1 more

Conditions: Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
Interventions: tolododekin alfa, Cemiplimab; Drug
Lead sponsor: Ankyra Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more

Conditions: Radiculopathy, Myelopathy, Cervical Degenerative Disc Disease
Interventions: ATLANTIS™ Cervical Plate System and allograft, BRYAN Cervical Disc Prosthesis; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 21 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 38
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Campbell, California + 31 more

Conditions: Suicide, Mental Health Disorder, Anhedonia
Interventions: ViraBrite nudges; Behavioral
Lead sponsor: Ksana Health; Industry
Eligibility: 13 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
Interventions: Vatalanib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 143
States / cities: Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 113 more

Conditions: Bacterial Conjunctivitis
Interventions: AzaSite, Tobramycin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Year and older
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 26
States / cities: Birmingham, Alabama • Littleton, Colorado • Atlantis, Florida + 23 more

Conditions: Ganglioneuroblastoma, High Risk Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, External Beam Radiation Therapy, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more

Conditions: Pedal Pad Atrophy, Diabetes Mellitus
Interventions: Year A Pathway, Year B Pathway; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy
Interventions: Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 22 more

Conditions: Colorectal Cancer
Interventions: xBar™ System; Device
Lead sponsor: Exero Medical Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Louisville, Kentucky • Baltimore, Maryland • Lincoln, Nebraska + 2 more

Conditions: Osteoarthritis, Joint Diseases
Interventions: Traditional exercise therapy for knee osteoarthritis, Knee stability training; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 40 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anal Cancer
Interventions: cisplatin, fluorouracil, mitomycin C, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2016
U.S. locations: 484
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 331 more

Conditions: Lung Cancer
Interventions: filgrastim, pegfilgrastim, cisplatin, docetaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 76
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Concord, California + 64 more

Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IIIA Ovarian Cancer 2014, FIGO Stage IIIA1 Ovarian Cancer, FIGO Stage IIIA2 Ovarian Cancer, FIGO Stage IIIB Ovarian Cancer 2014, FIGO Stage IIIC Ovarian Cancer 2014, FIGO Stage IVA Ovarian Cancer 2014, FIGO Stage IVB Ovarian Cancer 2014, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions: Carboplatin, Paclitaxel, Ruxolitinib Phosphate, Therapeutic Conventional Surgery; Drug · Procedure
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 110
States / cities: Goodyear, Arizona • Auburn, California • Los Angeles, California + 87 more

Search by objective public record fields.

A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children

Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin

PreHospital Air Medical Plasma Trial

Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)

Glyburide (RP-1127) for Traumatic Brain Injury (TBI)

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF

Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Fat Grafting for Pedal Fat Pad Atrophy in Diabetics

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar

Knee Stability Training for Knee Osteoarthritis (OA)

Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer